Source
21 Jul 2016
Re: Trading update nice update from Finncap too:-"... The strong cash generation also resulted in a special dividend of 3p per share.Tristel is also debt free with a cash balance of £15.7mln.“The weakness in non-chlorine dioxide products did not fully materialise in H2 FY 2016 as we had expected, which together with continuing robust overseas growth, has led to upgrades to FY 2016 and 2017 forecasts,” said analysts at finnCap.The broker’s forecast for profit before tax increased from £0.2m and £0.3m to £3.1m and £3.5m in 2016 and 2017 respectively.finnCap raised its target price to 130p."
Callun
21 Jul 2016
Trading update Excellent update. Excellent companyImproved income, improved profit.Debt free with forward plans to maintain a cash surplus.Cash generative with a return to shareholders via a special dividend.SP responded accordingly.Callun
Callun
11 Jul 2016
Re: Down The open day on 21st may provide some answers, but that's a long way off in this volatile market.Having almost reached saturation sales point in the UK a lot of the hoped for growth depends on achieving regulatory approval in the States, as you have indicated. Paul Swinney put no time scale on that goal being achieved, and I suspect that there may be one or two hurdles delaying meaningful progress there. Brexit may have come into play there, though I hope not.I am also a long term holder, and intend to add on further weakness. I like the open and investor friendly management style, and barring unforseen external calamities, am confident that steady rather than spectacular growth will be achieved. Nice and steady will do for me. As always, it's the timing that is difficult to predict.
AndyRB
08 Jul 2016
Re: Down High volumes to-day so maybe somebody is selling up , could bounce hard if the update is good but I don't think the market has yet forgiven the share based payments in the last accounts . America is all to play for but could be expensive so get approval etc. Been here a long time and not selling , might buy some more on further weakness but its hard to judge anything at the moment.
Callun
08 Jul 2016
Down Having survived Brexit relatively unscathed the SP has taken a significant dive this week on no news that I can find. I would have thought that the weaker pound would have helped overseas sales, and domestic sales should not be affected. Any thoughts? Callun
mcescher
30 Mar 2016
Solid dividend player with healthy balance sheet. From this excellent report on Tristel [link]
alecro
08 Mar 2016
Europe looks good too "Swinney said: “We are very pleased with the platform we have built in Germany. The progress we have made in Europe’s largest hospital market is evident in the fact that Germany’s contribution to group worldwide sales is now approaching 10 per cent. However, there is still enormous potential to exploit if the level of our German sales is to match the UK’s.” - See more at: [link]
Callun
29 Feb 2016
Re: NEW ARTICLE: Tristel: Would you buy ... There is no guidance given regarding when US approvals may be achieved. Paul Swinney emphasised this in his presentation, and cited the uncertainty as his reason for the more reserved tone in growth prospects in any timeframe. The level of approval required for eachindividual product has to be decided, and the approval body to which submissions made confirmed. Then the necessary tests have to be run and the correct paperwork posted before we see tangible progress.It could be 2016, but even if it is the market has to be started and sales growth established before it will affect the bottom line.That said, I too topped up, but expect the SP to remain volatile until some of thespeculative unknowns are cleared away.
alecro
29 Feb 2016
Re: NEW ARTICLE: Tristel: Would you buy now? 35% drop in the share price after ..... 36% rise in pre-tax profit ..... revenue abroad grew 20%, .......have taken a big share of the market in the UK, and may well repeat the trick worldwide.Regulatory approval soon in US should see TSTL clean up there 2016 imho! Bought in on this lucky dip.DYOR
seadoc
27 Feb 2016
Re: Webinar recording now available Thank you.
equity_dev
26 Feb 2016
Webinar recording now available If you would like to view the webinar from yesterday it is now available at:[link] Equity Development team
Callun
26 Feb 2016
Re: NEW ARTICLE: Tristel: Caught in the expe... From the link:"The lesson for investors, is not to be seduced by management targets but recognise they are ambitions that may not be fulfilled. We should make our own, usually more conservative, expectations. Oh, and to scrutinise mundane looking announcements about share options more carefully."---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------Sums up nicely the trap long term holders, myself included, fell into. In future I will pay more attention to those RNS notices awardingsignificant share options that have trigger points.Now that is behind us, and I must say that Paul Swinney seemed genuinely embarassed by the event, even whilst pocketing the windfall, the share price should hopefully recover some lost ground.Callun
II Editor
26 Feb 2016
NEW ARTICLE: Tristel: Caught in the expectations trap "Tristel’s share price has dived because it’s not doing as well as managers led credulous investors to believe. That isn’t to say it’s doing badly.Maybe it was the harsh office lighting, maybe it was the gruelling two-day schedule of ..."[link]
II Editor
26 Feb 2016
NEW ARTICLE: Tristel: Caught in the expectations trap "Tristel’s share price has dived because it’s not doing as well as managers led credulous investors to believe. That isn’t to say it’s doing badly.Maybe it was the harsh office lighting, maybe it was the gruelling two-day schedule of ..."[link]
Callun
25 Feb 2016
Webinar I listened in to todays webinar and was impressed by the tone, transparency and clarity of the presentation. It has certainly clarified some aspects of the results and added explanation for some of the criticism arising.Paul Swinney was emphatic that the share based payment is a one off, never to be repeated charge (caveated to at least not in the next 3-4 years).The persieved slowdown in growth comes down to factors beyond Tristel control e.g. the time it will take for regulatory approval, particularly in the US, and a reluctance to forecast a growth that may take more time to crystailise than the predictiion period.UK sales are more difficult to grow, mainly because of the current depth of market penetration, and the reluctance of faceless procurement staff in the NHS to embrace technology improvements for which there is no current budget.On the whole a very positive presentation,with management continuing to be open with shareholders, and despite the recent savage SP fall has given me the confidence to top up my holding.Recovery may be slow, but there seems to be no overiding business argument against it.Callun
